TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The CDC’s 2026 Antimicrobial Resistance Threats Report lists 19 pathogens across urgent, serious and concerning threat levels, plus six on a watch list. Together, the pathogens are estimated to cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are classified as urgent threats.
The CDC’s updated 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens that pose threats to public health and estimates they cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are in the agency’s highest, “urgent” category, while six additional pathogens appear on a watch list.
The CDC’s urgent list includes Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. These organisms can cause infections that are difficult to treat because resistance limits the antibiotics available, though the risks and circumstances vary by pathogen.
The report also identifies several changes in its threat categories. Drug-resistant meningococcal disease is now classified as a serious threat requiring prompt, sustained action. Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria were added to the watch list, which covers potential threats with uncertain disease burdens.
Clostridioides difficile moved down from urgent to serious. The source report says the change was driven in part by infection-prevention measures that have reduced cases since 2011. A lower category does not mean the pathogen no longer poses a serious health risk.
Resistance Can Limit Routine Care
Antimicrobial resistance can make infections harder to treat and raises the stakes for people who are already seriously ill or receiving hospital care. The CDC’s combined estimate—50,800 deaths a year across the pathogens in the report—shows the scale of the problem, while the individual threats can affect patients in distinct settings.
Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase health-care costs. She also warned they can make it harder for clinicians to provide care such as chemotherapy, organ transplants and surgery safely. Those effects reach beyond infection treatment: procedures that depend on effective antibiotics may become more difficult when resistance narrows treatment options.
The report’s categories can help direct attention to pathogens that warrant public-health action, but the figures do not mean every person faces the same risk. Some of the listed organisms are especially concerning in hospitals and nursing homes; others, such as gonorrhea, spread through sexual contact.
Products Worth Considering
Levoit Vital 100S-P Air Purifier for Home and Pets
Levoit Core 600S-P Smart Air Purifier for Large Rooms
Oral-B iO Series 9 Limited Rechargeable Electric Toothbrush with 7 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
Four Pathogens in the Urgent Tier
The report describes C. auris as an emerging, multidrug-resistant yeast that can cause severe infections, especially in people with serious underlying conditions. Reported U.S. cases rose from 48 in 2016, when the organism was first reported in the country, to 4,523 in 2023. Those figures are reported cases, not an estimate of all infections.
Carbapenem-resistant Acinetobacter and Enterobacterales are serious concerns in health-care settings, including hospitals and nursing homes. The report says Acinetobacter was linked to 9,497 U.S. hospitalizations in 2023 and an estimated 817 deaths that year; 63% of cases began outside hospitals. Carbapenem-resistant Enterobacterales, which include some E. coli and Klebsiella, were linked to 14,878 hospitalizations and an estimated 1,252 deaths in 2023.
Drug-resistant gonorrhea can make treatment more difficult. The report estimates 787,000 U.S. infections in 2023 and says 55.4% of cases that year were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations. The source also notes that the FDA approved gepotidacin and zoliflodacin in 2025 as new antibiotics for gonorrhea, the first new antibiotics for the infection in decades.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Burden Varies Across Pathogens
The CDC’s 9.7 million infections and 50,800 deaths are estimates for the pathogens covered by the report, not counts of cases occurring in a single year. The supplied report does not specify the estimation period or methodology behind those combined annual figures, so they should not be read as a direct tally of confirmed cases and deaths from 2026.
The watch-list category carries additional uncertainty: the CDC identifies these organisms as possible emerging threats, but their disease burdens are not yet clear. The available source material also does not provide detailed methods for every pathogen estimate or explain how each category decision was reached. The effect of newly approved gonorrhea antibiotics on resistance and infection rates remains unknown from the material provided.
Federal Drug Bill Remains Stalled
Armstrong called for passage of the PASTEUR Act, a proposed federal program intended to support development of antimicrobial drugs against high-threat pathogens and infections. According to the source report, versions of the bill in both chambers of Congress remain stalled in committee. No further legislative timetable is provided.
The updated CDC report sets out the agency’s current threat classifications and estimates, but the source material does not announce a specific next reporting date or new public-health measures. Subsequent case data, research and policy decisions will help show whether the listed threats are changing and whether interventions are affecting their burden.
Key Questions
What does the CDC report estimate?
It estimates that the 19 pathogens covered cause 9.7 million infections and 50,800 deaths annually in the United States. The supplied source does not specify the underlying estimation period or methodology.
Which pathogens are classified as urgent threats?
The four named urgent drug-resistant threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower category?
The source report says C. difficile moved from urgent to serious, driven in part by infection-prevention measures that have reduced cases since 2011. It remains classified as a serious threat.
What is the CDC’s watch list?
It includes six potential threats whose disease burdens are uncertain. The source names drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria among the additions.
What is the PASTEUR Act?
It is proposed federal legislation intended to create a program to develop antimicrobial drugs for high-threat pathogens and infections. The source report says versions in both chambers remain stalled in congressional committees.
Source: medpagetoday.com
